Last updated: 2026-09-08 13:15:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Senseonics Holdings, Inc. (SENS) operates in the INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL sector and is listed on NASDAQ. The stock is currently priced at $9,70, with a market capitalization of $509,18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,79 to $11,58. This page covers its latest market performance, valuation, price trends and company information.
$509,18M | |
$9,73 | |
$111,20 | |
$4,79 | |
-- | |
709,00 | |
742,12K | |
-- | |
$11,58 | |
$4,79 | |
-- | |
-- |
Senseonics Holdings, Inc. (SENS) is trading at $9,89 in pre-market trading as of 2026-09-08 12:58:00, -- from the previous close of $0,00
Pre-market trading shows how investors are pricing SENS before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Senseonics Holdings, Inc. (SENS) moved from $9,40 to $9,70, representing a gain of 3,14% ($0,29).
The stock traded between $9,09 and $10,15 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 561,80 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 72,3%
SENS is currently trading at $9,70, placing it 72,3% of the way from its 52-week low of $4,79 to its 52-week high of $11,58. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
| Industry | INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Senseonics Holdings, Inc. (SENS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.